Hemp Beverage Companies Face Existential Threat Under 0.4mg THC Container Limit
The hemp beverage industry regulation faces a critical challenge with the new federal THC limit of 0.4mg per container. This limit threatens the legality of many popular low-dose THC seltzers and beverages. The industry's future depends on how…
Wageningen Scientists ‘Resurrect’ Ancient Cannabis Enzymes with Medical Promise
Ancient cannabis enzymes hold the key to producing CBC, a promising anti-inflammatory cannabinoid. Wageningen scientists reconstructed these enzymes, which can produce THC, CBD, and CBC simultaneously. This breakthrough in ancient cannabis enzymes opens…
Top Issues in Cannabis Industry 2026: Hemp Redefinition & Market Changes
Cannabis hemp redefinition 2026 will reclassify popular hemp products as Schedule I substances, impacting legality and banking. This shift tightens regulations and market access. Understanding these changes is crucial for industry stakeholders.
How the 2026 Farm Bill Supports Industrial Hemp Producers
The 2026 farm bill industrial hemp regulation offers protections for industrial hemp farmers while excluding cannabinoid hemp products. This legislation reduces testing and background check requirements for hemp producers. However, it leaves cannabinoid…
FDA Misses Deadline to Publish Cannabinoid Classification Lists
The FDA missed the cannabinoid classification deadline mandated by Congress, creating uncertainty for hemp CBD products. This delay impacts compliance with the upcoming 2026 hemp ban. Stakeholders urge Congress to reconsider the timeline due to this…
Prenatal Cannabis Exposure Study: 9 Clear Findings
A new prenatal cannabis exposure study used meconium testing and Medicaid claims to examine well-child visits, ED use, and developmental delay coding. The headline is simple: no signal of increased utilization burden, and no higher developmental delay by…
Is Cannabis Safe for Seniors With Chronic Pain? A Doctor’s Evidence Review
Cannabis chronic pain older adults use is complex and nuanced. Some seniors report meaningful pain relief and reduced opioid use. However, risks like falls and drug interactions require careful consideration.
The Medicine Behind the Market : Part III/ IV — The Recovery: When the Market Learns to Heal
Healing rarely begins with profit; it starts with cannabis clinical literacy and pattern recognition. The recovery phase emerges as companies measure outcomes and respect the endocannabinoid system. This approach rebuilds trust and aligns economics with…
The Medicine Behind the Market : Part I — The Fever: When the Market Forgot Its Pulse
The cannabis industry medical neglect has led to market volatility and patient dissatisfaction. Patients seek efficacy, not just products. This article examines the disconnect between market trends and patient needs.
Cannabis Use Disorder Heart Attack Study: 7 Crucial Reality Checks
The cannabis use disorder heart attack study highlights increased cardiovascular risk in hospitalized MASH cirrhosis patients. This analysis clarifies that the study measured diagnosis codes, not direct cannabis exposure. Understanding these nuances…